Geoffrey Porges
Stock Analyst at SVB Leerink
(1.33)
# 3,593
Out of 4,996 analysts
122
Total ratings
42.86%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $23.76 | +135.69% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $12.84 | +678.82% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $563.90 | +50.74% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $73.75 | -34.92% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $272.98 | -20.87% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $220.61 | -38.81% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $15.17 | -27.49% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $112.10 | -33.10% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $45.54 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $14.07 | -28.93% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $12.31 | +5,992.61% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $385.74 | -54.63% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $24.73 | +239.67% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $39.85 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $6.80 | +797.06% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $137.37 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $23.76
Upside: +135.69%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $12.84
Upside: +678.82%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $563.90
Upside: +50.74%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $73.75
Upside: -34.92%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $272.98
Upside: -20.87%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $220.61
Upside: -38.81%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $15.17
Upside: -27.49%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $112.10
Upside: -33.10%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $45.54
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $14.07
Upside: -28.93%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $12.31
Upside: +5,992.61%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $385.74
Upside: -54.63%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $24.73
Upside: +239.67%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $39.85
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $6.80
Upside: +797.06%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $137.37
Upside: -